Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma

International Journal of Cancer

Volumn 134, Issue 2, 2014, Pages 342-351

  Cui, Jiuwei ^a   Wang, Nanya ^a   Zhao, Hengjun ^a   Jin, Haofan ^a   Wang, Guanjun ^a   Niu, Chao ^a   Terunuma, Hiroshi ^b   He, Hua ^a   Li, Wei ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Biotherapy Institute of Japan   (Japan)

Author keywords

cellular immunotherapy; hepatocellular carcinoma; radiofrequency ablation

Indexed keywords

ANTIBODY;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNOTHERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; SUPPRESSOR CELL; VIRUS LOAD;

CELLULAR IMMUNOTHERAPY; HEPATOCELLULAR CARCINOMA; RADIOFREQUENCY ABLATION;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SURVIVAL RATE;

EID: 84887427672     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28372     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17. (Pubitemid 37518510)
3. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. (Pubitemid 43112690)
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30. (Pubitemid 32844200)
5. Garcea G, Lloyd TD, Aylott C, et al. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer 2003; 39: 2150-64. (Pubitemid 37297739)
6. Curley SA,. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003; 10: 338-47. (Pubitemid 40486929)
7. Tang TJ, Vukosavljevic D, Janssen HL, et al. Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol 2006; 37: 332-8. (Pubitemid 43277521)
8. Beckebaum S, Cicinnati VR, Dworacki G, et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002; 104: 138-50. (Pubitemid 35026224)
9. Friedl J, Stift A, Paolini P, et al. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 2000; 15: 477-86.
10. Finn OJ,. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 630-41. (Pubitemid 37328666)
11. Dudley ME, Rosenberg SA,. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-75. (Pubitemid 37328821)
12. Drake CG, Jaffee E, Pardoll DM,. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81. (Pubitemid 43765799)
13. Pantuck AJ, Zisman A, Belldegrun AS,. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-23.
14. Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66: 1139-46. (Pubitemid 43165983)
15. Fatourou EM, Koskinas JS,. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Rev Anticancer Ther 2009; 9: 1499-510.
16. Fagnoni FF, Zerbini A, Pelosi G, et al. Combination of radiofrequency ablation and immunotherapy. Front Biosci 2008; 13: 369-81. (Pubitemid 351594784)
17. Fisch P, Moris A, Rammensee HG, et al. Inhibitory MHC class I receptors on gammadelta T cells in tumour immunity and autoimmunity. Immunol Today 2000; 21: 187-91. (Pubitemid 30184789)
18. Cooper MA, Colonna M, Yokoyama WM,. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep 2009; 10: 1103-10.
19. Cruz-Munoz ME, Veillette A,. Do NK cells always need a license to kill? Nat Immunol 2010; 11: 279-80.
20. Algarra I, Garcia-Lora A, Cabrera T, et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904-10. (Pubitemid 39312657)
21. Ljunggren HG, Karre K,. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-44. (Pubitemid 20198988)
22. Maniar A, Zhang X, Lin W, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116: 1726-33.
23. Brandes M, Willimann K, Bioley G, et al. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci USA 2009; 106: 2307-12.
24. Schmidt-Wolf IG, Lefterova P, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-9. (Pubitemid 24223014)
25. Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92: 3318-27. (Pubitemid 28492340)
26. Linn YC, Lau LC, Hui KM,. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002; 116: 78-86. (Pubitemid 34122063)
27. Franceschetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009; 37: 616-28.e2.
28. Takayama T, Makuuchi M, Sekine T, et al. Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer 1991; 68: 2391-6.
29. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-7.
30. Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28: 496-504.
31. Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract 2012; 66: 21-7.
32. Brittenden J, Heys SD, Ross J, et al. Natural killer cells and cancer. Cancer 1996; 77: 1226-43. (Pubitemid 26102319)
33. Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998; 83: 58-63. (Pubitemid 28299629)
34. McCoy JL, Rucker R, Petros JA,. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat 2000; 60: 227-34. (Pubitemid 30440538)
35. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17: 889-96.
36. Maksan SM, Araib PM, Ryschich E, et al. Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat. Dig Dis Sci 2004; 49: 859-65. (Pubitemid 38870215)
37. Iida N, Nakamoto Y, Baba T, et al. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. J Leukoc Biol 2008; 84: 1001-10.
38. Hadziyannis E, Sialevris K, Georgiou A, et al. Analysis of serum alpha-fetoprotein-L3% and des-gamma carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total alpha-fetoprotein levels. Oncol Rep 2013; 29: 835-9.
39. Rao P, Escudier B, de Baere T,. Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis. Cardiovasc Intervent Radiol 2011; 34: 424-30.
40. Dong BW, Zhang J, Liang P, et al. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia 2003; 19: 119-33. (Pubitemid 36304681)
41. den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64: 4024-9. (Pubitemid 38697319)
42. Zhou P, Liang P, Dong B, et al. Phase clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther 2011; 11: 450-6.
43. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008; 31: 63-71. (Pubitemid 351619405)
44. Ma H, Zhang Y, Wang Q, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther 2010; 9: 903-7.
45. Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellualar carcinoma serum markers. Semin Oncol 2012; 39: 410-33.
46. Kozlowska E, Biernacka M, Ciechomska M, et al. Age-related changes in the occurrence and characteristics of thymic CD4(+) CD25(+) T cells in mice. Immunology 2007; 122: 445-53. (Pubitemid 47556482)
47. Kryczek I, Liu R, Wang G, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69: 3995-4000.
48. Chang IS, Shin SW, Cho SK, et al. Evolution of portal vein tumor thromboses in patients with hepatocellular carcinoma: CT findings and transition of serum tumor markers. Clin Imaging 2012; 36: 489-95.
49. Pardee AD, Butterfield LH,. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 2012; 1: 48-55.
50. Masuzaki R, Karp SJ, Omata M,. New serum markers of hepatocellular carcinoma. Semin Oncol 2012; 39: 434-9.